Committed to the Safety of Patients
Boehringer Ingelheim works to discover and develop innovative, safe and effective ways to treat and prevent some of the world's most challenging diseases.
Clinical trial programme
As an innovative pharmaceutical company, Boehringer Ingelheim has a large and experienced global team managing and conducting clinical trials in many indications. We are committed to the safety of patients who take part in our clinical trials and holding the highest standards in all of our research initiatives. Such trials are conducted to establish the potential of drugs under investigation to progress to becoming new medicines. They are fundamental to developing novel treatments of therapeutic benefit.
Our trials are conducted according to agreed international standards and in compliance with all respective regulations.
In the past decade, Boehringer Ingelheim conducted or sponsored about 1400 studies including 1.2 million patients. Study centres are located in 59 countries all over the world.
Our main clinical trials are ongoing for prevention of
- Cardiovascular diseases
- Respiratory diseases
- Cerebrovascular diseases
Focus on clinical research
Explore the indication areas of Boehringer Ingelheim clinical trials.
